Multispecific Antibody Therapeutics Clinical Trials FDA Approved Multispecific Antibodies Market Size Insight
26. August 2024 02:44 ET
|
KuicK Research
Delhi, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Multispecific antibody therapeutics are rapidly emerging as a transformative approach in the treatment of various diseases, particularly cancer, autoimmune...
Multispecific Antibody Development Clinical Trials Sales Market Size Insight
30. Juni 2023 07:28 ET
|
KuicK Research
Delhi, June 30, 2023 (GLOBE NEWSWIRE) -- The development of multispecific antibodies, which have the potential to change the way cancer is treated, has been positively influenced by the commercial...
Global Tetraspecific Antibody Market Opportunity Clinical Development Report
22. März 2023 08:17 ET
|
KuicK Research
Delhi, March 22, 2023 (GLOBE NEWSWIRE) -- Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Companies & Market Trends Insight 2023 Report Highlights: Global Tetraspecific...
Cytovia Therapeutics’ Leadership to Present at Upcoming Conferences
29. März 2022 10:56 ET
|
Cytovia Therapeutics
AVENTURA, Fla. and NATICK, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell...
Evelyn D’An Joins Cytovia Therapeutics as Chief Financial Officer
12. Oktober 2021 12:24 ET
|
Cytovia Therapeutics
AVENTURA, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc. (“Cytovia”), a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen...
Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline
13. September 2021 10:08 ET
|
Cytovia Therapeutics
Cytovia eligible for up to $400 million in licensing milestones for Greater China rightsCoordinated US and China clinical development of GPC3-targeted therapies for hepatocellular carcinoma AVENTURA,...
Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October 2020
29. September 2020 16:00 ET
|
Cytovia Therapeutics
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in...
Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic
12. August 2020 09:04 ET
|
Cytovia Therapeutics
NEW YORK and LEIDEN, the Netherlands, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing CAR NK cell therapy and NK engager...
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer
03. Juni 2020 13:25 ET
|
Cytovia Therapeutics
NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces...
Hebrew University to Collaborate with Cytovia Therapeutics
18. März 2020 09:00 ET
|
Cytovia Therapeutics
NEW YORK and JERUSALEM, March 18, 2020 (GLOBE NEWSWIRE) -- Yissum, the technology transfer company of The Hebrew University of Jerusalem and Cytovia Therapeutics, Inc, a biopharmaceutical company...